This site is intended for Healthcare professionals only.
×

FDA granted priority review to Novartis for combo therapy for melanoma


FDA granted priority review to Novartis for combo therapy for melanoma

ZURICH: The U.S. Food and Drug Administration has granted priority review for Novartis’s Tafinlar in combination with Mekinist for treating some patients with advanced melanoma, the Swiss drugmaker said.

The review covers the combination therapy for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations following complete resection.

In October, the FDA also granted breakthrough therapy designation to Tafinlar in combination with Mekinist for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection, the company said in a statement.

(Reporting by Michael Shields; Editing by Vyas Mohan)

The following two tabs change content below.
Ruby Khatun

Ruby Khatun

Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: REUTERS
0 comment(s) on FDA granted priority review to Novartis for combo therapy for melanoma

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted